Author

Ciprian Tomuleasa

Iuliu Hatieganu University of Medicine and Pharmacy Cluj Napoca - Cited by 3,966

Biography

   Ciprian Tomuleasa  is working at  University of Medicine and Pharmacy  in Romania. International experience includes various programs, contributions and participation in different countries for diverse fields of study and interests reflect in wide range of publications in various national and international journals
Title
Cited by
Year
SERS liquid biopsy: An emerging tool for medical diagnosis
V Moisoiu, SD Iancu, A Stefancu, T Moisoiu, B Pardini, MP Dragomir, ...Colloids and Surfaces B: Biointerfaces 208, 112064, 2021202
37
2021
Coagulopathy in acute promyelocytic leukemia: can we go beyond supportive care?
BC Hambley, C Tomuleasa, G GhiaurFrontiers in Medicine 8, 722614, 2021202
13
2021
Extramedullary hematopoiesis of the liver and spleen
D Cenariu, S Iluta, AA Zimta, B Petrushev, L Qian, N Dirzu, C Tomuleasa, ...Journal of clinical medicine 10 (24), 5831, 2021202
13
2021
Patient selection for CAR T or BiTE therapy in multiple myeloma: Which treatment for each patient?
D Kegyes, C Constantinescu, L Vrancken, L Rasche, C Gregoire, B Tigu, ...Journal of Hematology & Oncology 15 (1), 78, 2022202
11
2022
SERS-based DNA methylation profiling allows the differential diagnosis of malignant lymphadenopathy
A Stefancu, V Moisoiu, M Desmirean, SD Iancu, AB Tigu, B Petrushev, ...Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy 264, 120216, 2022202
9
2022
The Potential Advantage of Targeting Both PD-L1/PD-L2/PD-1 and IL-10–IL-10R Pathways in Acute Myeloid Leukemia
L Jimbu, O Mesaros, A Neaga, AM Nanut, C Tomuleasa, D Dima, ...Pharmaceuticals 14 (11), 1105, 2021202
7
2021
Current therapeutic approaches in the management of hemophilia—a consensus view by the Romanian Society of Hematology
I Hotea, M Brinza, C Blag, AA Zimta, N Dirzu, C Burzo, I Rus, D Apostu, ...Annals of Translational Medicine 9 (13), 2021202
7
2021
The Potential Equivalents of TET2 Mutations
S Pasca, A Jurj, M Zdrenghea, C TomuleasaCancers 13 (7), 1499, 2021202
6
2021
Real-world treatment patterns and clinical outcomes in patients with AML unfit for first-line intensive chemotherapy*
T Miyamoto, D Sanford, C Tomuleasa, HH Hsiao, LJE Olivera, AK Enjeti, ...Leukemia & Lymphoma 3 (4), 928-938, 2022202
6
2022
Unexplained hemorrhagic syndrome? Consider acquired hemophilia A or B
C Constantinescu, C Jitaru, S Pasca, D Dima, N Dirzu, D Coriu, ...Blood Reviews 3, 100907, 2022202
5
2022
Exploiting the ubiquitin system in myeloid malignancies. From basic research to drug discovery in MDS and AML
R Drula, S Iluta, D Gulei, C Iuga, D Dima, G Ghiaur, AD Buzoianu, ...Blood Reviews 6, 100971, 2022202
5
2022
The predictive role of modified early warning score in 174 hematological patients at the point of transfer to the intensive care unit
C Constantinescu, S Pasca, S Iluta, G Gafencu, M Santa, C Jitaru, ...Journal of Clinical Medicine 10 (20), 4766, 2021202
5
2021
The possible non-mutational causes of FVIII deficiency: non-coding RNAs and acquired hemophilia A
AA Zimta, I Hotea, M Brinza, C Blag, S Iluta, C Constantinescu, ...Frontiers in Medicine 8, 65197, 2021202
4
2021
Comparison of peripheral blood stem cell mobilization with filgrastim versus pegfilgrastim in lymphoma patients–single center experience
L Lipan, A Colita, L Stefan, C Calugaroiu, C Serban, C Tomuleasa, ...J BUON 26 (), 1080-1087, 2021202
3
2021
Healthcare resource utilization trends in patients with acute myeloid leukemia ineligible for intensive chemotherapy receiving first‐line systemic treatment or best supportive …
T Ito, D Sanford, C Tomuleasa, HH Hsiao, LJE Olivera, AK Enjeti, ...European Journal of Haematology 109 (1), 58-68, 2022202
3
2022
Database-guided analysis for Immunophenotypic diagnosis and follow-up of acute myeloid leukemia with recurrent genetic abnormalities
CM Aanei, R Veyrat-Masson, C Selicean, M Marian, L Rigollet, AP Trifa, ...Frontiers in Oncology 11, 746951, 2021202
3
2021
Haematology patients infected with SARS-CoV-2, pretreated with eculizumab or siltuximab, develop oligosymptomatic disease
S Iluta, S Pasca, D Dima, G Mester, L Urian, A Bojan, M Zdrenghea, ...European Journal of Hospital Pharmacy 29 (6), e8-e8, 2022202
3
2022
SERS-Based Evaluation of the DNA Methylation Pattern Associated With Progression in Clonal Leukemogenesis of Down Syndrome
V Moisoiu, V Sas, A Stefancu, SD Iancu, A Jurj, S Pasca, S Iluta, AA Zimta, ...Frontiers in Bioengineering and Biotechnology 9, 70268, 2021202
3
2021
Mobile health technology for the personalized therapy of hemophilia
N Dirzu, I Hotea, C Jitaru, M Brinza, L Urian, MC Peters, K Gal, L Popescu, ...Frontiers in Medicine 8, 71197, 2021202
3
2021
Characteristics of Dental Resin-Based Composites in Leukemia Saliva: An In Vitro Analysis
A Mester, M Moldovan, S Cuc, C Tomuleasa, S Pasca, M Filip, A Piciu, ...Biomedicines 9 (11), 1618, 010
2
2021

Referred From: https://scholar.google.ro/citations?user=QayNc9IAAAAJ&hl=en

Cited by
Citations 3966
h-index 34
i10-index 93
Recommended Journals
Open Access Journals